Leucine Aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Aakriti Jain,Isaac Heremans,Gilles Rademaker,Tyler Detomasi,Peter Rohweder,Dashiell Anderson,Justin Zhang,Grace Hernandez,Suprit Gupta,Teresa von Linde,Mike Lange,Martina Spacci,Yemima Citron,James Olzmann,David Dawson,Charles Craik,Guido Bommer,Rushika M Perera,Roberto Zoncu
DOI: https://doi.org/10.1101/2024.12.13.628212
2024-12-14
Abstract:Proteolysis of hydrophobic helices is required for complete breakdown of every transmembrane protein trafficked to the lysosome and sustains high rates of endocytosis. However, the lysosomal mechanisms for degrading hydrophobic domains remain unknown. Combining lysosomal proteomics with functional genomic data mining, we identify Lysosomal Leucine Aminopeptidase (LyLAP; formerly Phospholipase B Domain-Containing 1) as the hydrolase most tightly associated with elevated endocytic activity. Untargeted metabolomics and biochemical reconstitution demonstrate that LyLAP is not a phospholipase, but a processive monoaminopeptidase with strong preference for N-terminal leucine - an activity necessary and sufficient for breakdown of hydrophobic transmembrane domains. LyLAP is upregulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake, and its ablation led to buildup of undigested hydrophobic peptides, which compromised lysosomal membrane integrity and inhibited PDA cell growth. Thus, LyLAP enables lysosomal degradation of membrane proteins, and may represent a vulnerability in highly endocytic cancer cells.
Biochemistry